CA
NZ
UK
AU
IND
US
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) disclosed on July 6, 2026 that its optimized oral version of SKNY‑1 demonstrated promising pharmacokinetic properties in a series of preclinical studies. The company highlighted the drug’s potential for treating obesity and addiction‑related disorders based on the new data.
Nuvation Bio Inc. (NYSE: NUVB) closed a registered underwritten public offering that generated $287.5 million in gross proceeds.
Oragenics Inc has promoted its Senior Controller to the position of Chief Financial Officer, signaling a strategic move as the healthcare company refines its financial operations. The transition aligns with broader corporate developments, including updated executive compensation and shareholder-approved measures that may influence the …
Omeros Corp. (NASDAQ: OMER) is moving ahead with a debt‑reduction plan that includes buying back $16.0 million of principal tied to its 9.50% convertible notes that mature in 2029. The deal, reached via privately negotiated agreements with certain holders, is slated to close on …
Polomar Health Services Inc. (OTC: PMHS) filed a corporate governance update on July 1, 2026 that reshapes its board composition, senior management, and equity compensation framework. The changes were adopted by unanimous written consent and are intended to support the company’s strategic objectives.
Profusa (NASDAQ: PFSA) has finalized its plans for a 1-for-25 reverse stock split after receiving shareholder approval during its annual meeting. The board authorized the CEO to determine the consolidation ratio, opting for 25 shares to be combined into one. This decision aligns with …
RxSight, Inc. Has entered into a pivotal collaboration with Alcon, aiming to advance innovation in intraocular lens technology. The RxSight-Alcon Collaboration Agreement, effective June 30, 2026, establishes a framework for developing light-adjustable versions of certain simultaneous vision intraocular lenses, representing a meaningful progression in …
SAB Biotherapeutics (NASDAQ: SABS) announced a collaboration with Breakthrough T1D to advance its SAB-142 therapy for Stage 3 type 1 diabetes. The grant supports the PRISE-hATG clinical study, led by Dr. Michael J. Haller at the University of Florida, targeting patients recently diagnosed with …
Galera Therapeutics Inc. Has received board approval for a 1-for-200 reverse stock split of its common stock, par value $0.001. The decision aligns with the company’s strategic objectives as it advances its clinical programs targeting radiation-induced side effects in cancer treatment.
Greater Cannabis Company Inc. (OTC: GCAN) has experienced a major shift in governance, as Trafalgar Asset Management, LLC has established a commanding position in the company’s voting structure. This development follows the firm’s accumulation of a dominant stake in the company’s securities, reflecting a …
Please wait processing your request...